Recovery and assessment timescales in hypertension extend from weeks to months. Initial post-infusion inflammatory responses typically resolve within 1–2 weeks; temporary blood-pressure fluctuations may occur during this window. Meaningful blood-pressure reduction usually requires 4–12 weeks to become apparent. Home blood-pressure monitoring (morning and evening readings) is standard to track gradual reduction. Formal cardiovascular assessment — office visits, 24-hour ambulatory blood-pressure monitoring, vascular-stiffness testing — is repeated at 8, 16, and 24 weeks post-infusion. Patients should expect gradual decline in blood pressure rather than acute drops. Antihypertensive medication should not be abruptly withdrawn; dose adjustments follow clinical response over weeks.
Clinical hypertension trials show preliminary promise but remain modest in sample size and follow-up duration. Four actively recruiting trials indicate continuing clinical interest. Published studies document reductions in systolic and diastolic blood pressure (5–15 mmHg average decreases) and improvements in vascular stiffness markers following MSC or exosome infusion. Flow-mediated dilation (endothelial function) showed improvement in responsive cohorts. Left-ventricular mass index decreased in some long-term follow-up assessments. However, heterogeneous patient populations, variable blood-pressure definitions, and concurrent antihypertensive medication use limit interpretation. Mechanism studies suggest paracrine effects driving benefit, but direct in-vivo confirmation remains sparse. Durability of blood-pressure reduction beyond 12 months is incompletely characterised.
Am I a candidate? → · Arterial Hypertension: full overview → · Arterial Hypertension cost → · Cost →
Medically reviewed by StemCellAtlas’s editorial team with Dr Polina Krasenova (Haematologist · Clinical Haematology & Integrative Oncology · 15+ yrs cell therapy) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
Médecine régénérative certifiée GMP au cœur de l'UE — à partir de 3 000–8 000 €, une fraction des prix américains ou allemands. Protocoles personnalisés pour patients de plus de 50 pays.
Évaluation médicale gratuite